193 related articles for article (PubMed ID: 37024879)
21. Plasma miRNAs as biomarkers for endometriosis.
Vanhie A; O D; Peterse D; Beckers A; Cuéllar A; Fassbender A; Meuleman C; Mestdagh P; D'Hooghe T
Hum Reprod; 2019 Sep; 34(9):1650-1660. PubMed ID: 31411334
[TBL] [Abstract][Full Text] [Related]
22. Lncrna ANGPTL1-3 and its target microRNA-30a exhibit potency as biomarkers for bortezomib response and prognosis in multiple myeloma patients.
Zhou F; Guo L
Hematology; 2022 Dec; 27(1):596-602. PubMed ID: 35617291
[TBL] [Abstract][Full Text] [Related]
23. Epigenetic silencing of miR-340-5p in multiple myeloma: mechanisms and prognostic impact.
Li Z; Wong KY; Calin GA; Chng WJ; Chan GC; Chim CS
Clin Epigenetics; 2019 May; 11(1):71. PubMed ID: 31064412
[TBL] [Abstract][Full Text] [Related]
24. Paired miRNA- and messenger RNA-sequencing identifies novel miRNA-mRNA interactions in multiple myeloma.
Aass KR; Nedal TMV; Tryggestad SS; Haukås E; Slørdahl TS; Waage A; Standal T; Mjelle R
Sci Rep; 2022 Jul; 12(1):12147. PubMed ID: 35840794
[TBL] [Abstract][Full Text] [Related]
25. The Relationship between Serum miRNAs and Early Mortality in Multiple Myeloma Patients Treated with Bortezomib-Based Regimens.
Puła A; Robak P; Jarych D; Mikulski D; Misiewicz M; Drozdz I; Fendler W; Szemraj J; Robak T
Int J Mol Sci; 2023 Feb; 24(3):. PubMed ID: 36769265
[TBL] [Abstract][Full Text] [Related]
26. Epigenetic regulation of
Pilala KM; Papadimitriou MA; Panoutsopoulou K; Barbarigos P; Levis P; Kotronopoulos G; Stravodimos K; Scorilas A; Avgeris M
Mol Ther Nucleic Acids; 2022 Dec; 30():311-322. PubMed ID: 36320325
[TBL] [Abstract][Full Text] [Related]
27. Circulating Small Noncoding RNAs Have Specific Expression Patterns in Plasma and Extracellular Vesicles in Myelodysplastic Syndromes and Are Predictive of Patient Outcome.
Hrustincova A; Krejcik Z; Kundrat D; Szikszai K; Belickova M; Pecherkova P; Klema J; Vesela J; Hruba M; Cermak J; Hrdinova T; Krijt M; Valka J; Jonasova A; Merkerova MD
Cells; 2020 Mar; 9(4):. PubMed ID: 32224889
[TBL] [Abstract][Full Text] [Related]
28. Prognostic and predictive value of a microRNA signature in stage II colon cancer: a microRNA expression analysis.
Zhang JX; Song W; Chen ZH; Wei JH; Liao YJ; Lei J; Hu M; Chen GZ; Liao B; Lu J; Zhao HW; Chen W; He YL; Wang HY; Xie D; Luo JH
Lancet Oncol; 2013 Dec; 14(13):1295-306. PubMed ID: 24239208
[TBL] [Abstract][Full Text] [Related]
29. MiR-182-5p and its target HOXA9 in non-small cell lung cancer: a clinical and in-silico exploration with the combination of RT-qPCR, miRNA-seq and miRNA-chip.
Gao L; Yan SB; Yang J; Kong JL; Shi K; Ma FC; Huang LZ; Luo J; Yin SY; He RQ; Hu XH; Chen G
BMC Med Genomics; 2020 Jan; 13(1):3. PubMed ID: 31906958
[TBL] [Abstract][Full Text] [Related]
30. Identification of a novel microRNA cluster miR-193b-365 in multiple myeloma.
Unno K; Zhou Y; Zimmerman T; Platanias LC; Wickrema A
Leuk Lymphoma; 2009 Nov; 50(11):1865-71. PubMed ID: 19883314
[TBL] [Abstract][Full Text] [Related]
31. miR-221/222 cluster expression improves clinical stratification of non-muscle invasive bladder cancer (TaT1) patients' risk for short-term relapse and progression.
Tsikrika FD; Avgeris M; Levis PK; Tokas T; Stravodimos K; Scorilas A
Genes Chromosomes Cancer; 2018 Mar; 57(3):150-161. PubMed ID: 29181884
[TBL] [Abstract][Full Text] [Related]
32. Serum miR-22 as potential non-invasive predictor of poor clinical outcome in newly diagnosed, uniformly treated patients with diffuse large B-cell lymphoma: an explorative pilot study.
Marchesi F; Regazzo G; Palombi F; Terrenato I; Sacconi A; Spagnuolo M; Donzelli S; Marino M; Ercolani C; Di Benedetto A; Blandino G; Ciliberto G; Mengarelli A; Rizzo MG
J Exp Clin Cancer Res; 2018 May; 37(1):95. PubMed ID: 29716630
[TBL] [Abstract][Full Text] [Related]
33. Incorporating MicroRNA into Molecular Phenotypes of Circulating Tumor Cells Enhances the Prognostic Accuracy for Patients with Metastatic Breast Cancer.
Tan W; Liang G; Xie X; Jiang W; Tan L; Sanders AJ; Liu Z; Ling Y; Zhong W; Tian Z; Lin W; Gong C
Oncologist; 2019 Nov; 24(11):e1044-e1054. PubMed ID: 31300482
[TBL] [Abstract][Full Text] [Related]
34. Infrequent DNA methylation of miR-9-1 and miR-9-3 in multiple myeloma.
Zhang Q; Wang LQ; Wong KY; Li ZY; Chim CS
J Clin Pathol; 2015 Jul; 68(7):557-61. PubMed ID: 25855800
[TBL] [Abstract][Full Text] [Related]
35. Clinical utility of miR-143/miR-182 levels in prognosis and risk stratification specificity of BFM-treated childhood acute lymphoblastic leukemia.
Piatopoulou D; Avgeris M; Drakaki I; Marmarinos A; Xagorari M; Baka M; Pourtsidis A; Kossiva L; Gourgiotis D; Scorilas A
Ann Hematol; 2018 Jul; 97(7):1169-1182. PubMed ID: 29556721
[TBL] [Abstract][Full Text] [Related]
36. Identification and validation of potential prognostic and predictive miRNAs of epithelial ovarian cancer.
Prahm KP; Høgdall C; Karlsen MA; Christensen IJ; Novotny GW; Høgdall E
PLoS One; 2018; 13(11):e0207319. PubMed ID: 30475821
[TBL] [Abstract][Full Text] [Related]
37. Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor load.
Neben K; Jauch A; Hielscher T; Hillengass J; Lehners N; Seckinger A; Granzow M; Raab MS; Ho AD; Goldschmidt H; Hose D
J Clin Oncol; 2013 Dec; 31(34):4325-32. PubMed ID: 24145347
[TBL] [Abstract][Full Text] [Related]
38. Circulating microRNA profiling in patients with advanced non-squamous NSCLC receiving bevacizumab/erlotinib followed by platinum-based chemotherapy at progression (SAKK 19/05).
Joerger M; Baty F; Früh M; Droege C; Stahel RA; Betticher DC; von Moos R; Ochsenbein A; Pless M; Gautschi O; Rothschild S; Brauchli P; Klingbiel D; Zappa F; Brutsche M
Lung Cancer; 2014 Aug; 85(2):306-13. PubMed ID: 24928469
[TBL] [Abstract][Full Text] [Related]
39. Circulating microRNA expression is associated with genetic subtype and survival of multiple myeloma.
Huang JJ; Yu J; Li JY; Liu YT; Zhong RQ
Med Oncol; 2012 Dec; 29(4):2402-8. PubMed ID: 22447484
[TBL] [Abstract][Full Text] [Related]
40. Using MMRFBiolinks R-Package for Discovering Prognostic Markers in Multiple Myeloma.
Settino M; Cannataro M
Methods Mol Biol; 2022; 2401():289-314. PubMed ID: 34902136
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
